Because of the rapid development of acquired resistance during BRAFi monotherapy within months, combination therapy with BRAFi and MEK-inhibitors (MEKi) is currently standard in the treatment of BRAFV600mut-positive stage IV melanoma patients [11]. The gene discussed is MAP2K7; the disease is melanoma.